Latest news with #AnthonyVendetti
Business Insider
22-07-2025
- Business
- Business Insider
Why Is Helius Medical Technologies Stock (HSDT) Up 70% Today?
Helius Medical Technologies (HSDT) stock rocketed higher on Monday after the neurotechnology company announced a positive outcome for its Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program (SRP). This includes a double-blind randomized clinical trial that met its primary endpoint and confirmed minimal incidence of adverse events and good treatment tolerability. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Helius Medical Technologies noted that these outcomes support its planned submission to the U.S. Food and Drug Administration (FDA). It will submit the PoNS SRP for gait and balance deficit in patients with chronic symptoms of stroke via the Breakthrough Device Designation. HSDT stock was up 70.45% in pre-market trading on Monday, following a 6.08% rally on Friday. However, the stock was still down 98.23% year to date and 98.63% over the past 12 months. With today's rally came heavy trading, as some 10 million shares changed hands, compared to a three-month daily average of about 280,000 units. Is Helius Medical Technologies Stock a Buy, Sell, or Hold? Turning to Wall Street, only one analyst has covered Helius Medical Technologies in the past three months. Maxim Group analyst Anthony Vendetti has a Hold rating and a $2.90 price target for the shares, suggesting a possible 67.42% downside for HSDT stock.
Business Insider
28-06-2025
- Business
- Business Insider
Maxim Group Reaffirms Their Hold Rating on Aethlon Medical (AEMD)
In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Hold rating on Aethlon Medical (AEMD – Research Report). The company's shares closed yesterday at $1.25. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Vendetti covers the Healthcare sector, focusing on stocks such as Dermata Therapeutics, bioAffinity Technologies, Inc., and Helius Medical Technologies. According to TipRanks, Vendetti has an average return of -27.0% and a 23.28% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Aethlon Medical.
